U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 11 results

Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound that potently inhibits the...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Safingol, the synthetic L-threo-stereoisomer of endogenous (D-erythro-) sphinganine, is an inhibitor of protein kinase C and sphingosine kinase in vitro, and in some cell types has been implicated in ceramide generation and induction of apoptosis. Sa...
Staurosporine is an alkaloid isolated from the culture broth of Streptomyces staurosporesa. It exerts antimicrobial, hypotensive, and cytotoxic activity. The main biological activity of staurosporine is the inhibition of protein kinases through the p...
Rottlerin is a principal phenolic compound of the Kamala plant Mallotus philippinensis. It was thought to be a selective inhibitor of PKCδ (protein kinase Cδ) (IC50=3-6 uM). It also inhibits PKCα, PKCβ, PKCγ, PKCε, PKCη, PKCζ and eEF2K (CaMK III) (IC...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound that potently inhibits the...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Safingol, the synthetic L-threo-stereoisomer of endogenous (D-erythro-) sphinganine, is an inhibitor of protein kinase C and sphingosine kinase in vitro, and in some cell types has been implicated in ceramide generation and induction of apoptosis. Sa...

Showing 1 - 10 of 11 results